Equilibrative nucleoside transporter 1 (ENT1) (ENT1)

Equilibrative nucleoside transporter 1 (ENT1), encoded by the SLC29A1 gene, is a widely expressed transmembrane protein that facilitates the bidirectional transport of purine and pyrimidine nucleosides across cellular membranes (UniProt: Q99808). As a member of the solute carrier family 29, it plays a fundamental role in maintaining adenosine homeostasis, which is crucial for regulating purinergic signaling in the cardiovascular and central nervous systems (PubMed: 21930119). In the context of oncology, ENT1 is the primary mediator for the cellular uptake of several nucleoside analog prodrugs, including gemcitabine, cytarabine, and decitabine. The expression level of ENT1 on the cell surface is a critical determinant of the efficacy of these drugs, making it a vital predictive biomarker for treatment response in cancers such as pancreatic ductal adenocarcinoma and acute myeloid leukemia (PubMed: 24501550). Beyond its role in drug transport, ENT1 is a pharmacological target for inhibitors like dipyridamole and ticagrelor, which are used to modulate extracellular adenosine levels for anti-thrombotic and vasodilatory effects (DrugBank: DB00644). Related transporters in the ENT family, such as ENT2, ENT3, and ENT4, also contribute to nucleoside flux but differ in their substrate specificity and tissue distribution.

Other names

Solute carrier family 29 member 1SLC29A1Nitrobenzylthioinosine-binding proteinNBMPR-sensitive nucleoside transporterhENT1

Equilibrative nucleoside transporter 1 (ENT1) mediates the bidirectional, facilitated diffusion of purine and pyrimidine nucleosides across the plasma membrane, moving substrates down their concentration gradients (UniProt: Q99808). It is essential for the cellular uptake of nucleoside analog drugs, which are then phosphorylated into active cytotoxic metabolites that inhibit DNA synthesis. Additionally, ENT1 regulates the concentration of extracellular adenosine; its inhibition by drugs like dipyridamole prevents adenosine reuptake, thereby prolonging adenosine receptor activation and inducing vasodilation or anti-platelet effects (PubMed: 21930119).